MedTech Business - September 25, 2014
Sectra sells to US hospitals
Sectra has sold and installed its radiation dose monitoring system, Sectra DoseTrack, at five Connecticut hospitals within Hartford HealthCare (HHC). Backus Hospital, Hartford Hospital, The Hospital of Central Connecticut, MidState Medical Center, and Windham Hospital now gather and analyze dose data from all necessary modalities within their imaging departments through the use of Sectra DoseTrack. […]
Collaboration - September 25, 2014
MedImmune teams up with Cancer Research UK
AstraZeneca’s global biologics research and development arm MedImmune and Cancer Research UK, with its commercial arm, Cancer Research Technology (CRT), has entered into a collaboration. The aim is to establish a joint laboratory in Cambridge, UK. The new laboratory will focus on the discovery and development of novel biologic cancer treatments over an initial five-year period. AstraZeneca announces that scientists […]
MedTech Business - September 24, 2014
Unisense Fertilitech receives FDA clearance
Unisense Fertilitech A/S has received FDA clearance for its “Compare & Select” feature in the EmbryoViewer software. The software is an accessory to the company’s EmbryoScope time-lapse incubator which assists IVF professionals in selecting embryos for transfer. “We’re excited to receive the FDA 510(k) clearance for the EmbryoViewer software, and believe this will aid IVF […]
Pharma Diagnostics - September 24, 2014
Mobidiag launches test
Finnish molecular diagnostics company Mobidiag launches test for PCR-based diagnostics of gastroenteritis. The company announced on September 23 the European launch of Amplidiag Bacterial GE, marketed as a CE-IVD product under the Directive 98/79/EC on in vitro diagnostic medical devices. The test optimizes stool sample screening processes by utilizing qPCR technology for detection of eight gastroenteritis-causing bacteria. Amplidiag […]
Funding - September 24, 2014
BerGenBio granted drug discovery award
Oncology biopharmaceutical company BerGenBio has been granted a GBP 1.6 million seeding drug discovery award from the UK’s Wellcome Trust. The money will go to develop novel small molecule inhibitors against BGB002, its proprietary, novel cancer target. BGB002 controls tumour cell malignant features. This gene is up-regulated in several cancer types including the difficult to treat malignancies such as triple-negative-breast cancer. BerGenBio holds […]
Drug Development Pharma - September 23, 2014
Oxabact granted EMA orphan drug designation
OxThera AB’s product Oxabact has been granted an Orphan Drug Designation in the European Union for treatment of Short Bowel Syndrome (SBS). Oxabact is an oral product composed of highly concentrated live bacteria (Oxalobacter formigenes). OxThera is currently pursuing a clinical development program in the EU and in the US for the treatment of patients suffering from Primary […]
